4 results
Primary: To evaluate the efficacy of FF/UMEC/VI to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Secondary: Long term safety and other efficacy parameters.
Primary:To evaluate the effects of FF/UMEC/VI on lung function compared with FF/VI after 24 weeks of treatmentSecondary:To assess the efficacy (exacerbations), FEV1 3h post dose, asthma symptoms, safety and tolerability.
The study objective is to measure beta cell mass and function in subjects with type 1 diabetes during and shortly after the honeymoon phase, to determine whether the change in metabolic control is mainly caused by a decrease in the total number of…
The main study objective is to measure residual beta cell mass, indicated by the pancreatic uptake of Ga-68-exendin using quantitative PET, in type 1 diabetes patients with stable near-normal and unstable glucose control, to improve understanding of…